Guardant Health Current Ratio 2017-2021 | GH
For a detailed definition, formula and example for Current Ratio, check out our new background page here.
Current and historical current ratio for Guardant Health (GH) from 2017 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Guardant Health current ratio for the three months ending June 30, 2021 was 19.57.
| Guardant Health Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2021-06-30 |
$1.89B |
$0.10B |
19.57 |
| 2021-03-31 |
$2.03B |
$0.10B |
21.29 |
| 2020-12-31 |
$1.89B |
$0.07B |
28.27 |
| 2020-09-30 |
$1.09B |
$0.07B |
15.11 |
| 2020-06-30 |
$1.01B |
$0.07B |
14.42 |
| 2020-03-31 |
$0.61B |
$0.08B |
7.38 |
| 2019-12-31 |
$0.60B |
$0.07B |
8.21 |
| 2019-09-30 |
$0.58B |
$0.07B |
8.60 |
| 2019-06-30 |
$0.60B |
$0.06B |
10.59 |
| 2019-03-31 |
$0.51B |
$0.05B |
10.63 |
| 2018-12-31 |
$0.47B |
$0.05B |
9.99 |
| 2018-09-30 |
$0.30B |
$0.03B |
9.27 |
| 2018-06-30 |
$0.00B |
|
0.00 |
| 2018-03-31 |
$0.00B |
|
0.00 |
| 2017-12-31 |
$0.00B |
|
0.00 |
| 2017-09-30 |
$0.00B |
|
0.00 |
| 2016-12-31 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$11.077B |
$0.287B |
|
Guardant Health Inc. is a precision oncology company. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. It launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant Health Inc. is based in REDWOOD CITY, United States.
|
